CN106220713B - 一种蝎毒耐热合成肽及其用途 - Google Patents
一种蝎毒耐热合成肽及其用途 Download PDFInfo
- Publication number
- CN106220713B CN106220713B CN201610645111.7A CN201610645111A CN106220713B CN 106220713 B CN106220713 B CN 106220713B CN 201610645111 A CN201610645111 A CN 201610645111A CN 106220713 B CN106220713 B CN 106220713B
- Authority
- CN
- China
- Prior art keywords
- scorpion venom
- heat
- peptide
- scorpion
- synthetic peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 98
- 239000002795 scorpion venom Substances 0.000 title claims abstract description 95
- 239000003814 drug Substances 0.000 claims abstract description 17
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000003556 anti-epileptic effect Effects 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 27
- 239000000284 extract Substances 0.000 abstract description 21
- 238000002474 experimental method Methods 0.000 abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 15
- 206010015037 epilepsy Diseases 0.000 abstract description 15
- 229920001184 polypeptide Polymers 0.000 abstract description 15
- 241001465754 Metazoa Species 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 13
- 241001481692 Mesobuthus martensii Species 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 10
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 abstract description 7
- 238000004366 reverse phase liquid chromatography Methods 0.000 abstract description 7
- 125000000539 amino acid group Chemical group 0.000 abstract description 4
- 239000002131 composite material Substances 0.000 abstract description 4
- 238000001514 detection method Methods 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract description 4
- 238000012827 research and development Methods 0.000 abstract description 4
- 206010039966 Senile dementia Diseases 0.000 abstract description 3
- 238000002418 nanoflow liquid chromatography-electrospray ionisation mass spectrometry Methods 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 abstract 1
- 238000009533 lab test Methods 0.000 abstract 1
- 238000001819 mass spectrum Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 15
- 241000244206 Nematoda Species 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 230000035605 chemotaxis Effects 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 231100000331 toxic Toxicity 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 229960001416 pilocarpine Drugs 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 9
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000239226 Scorpiones Species 0.000 description 8
- 210000001130 astrocyte Anatomy 0.000 description 8
- 231100000668 minimum lethal dose Toxicity 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 7
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
- 231100000682 maximum tolerated dose Toxicity 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 210000004295 hippocampal neuron Anatomy 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 238000012449 Kunming mouse Methods 0.000 description 4
- 238000012347 Morris Water Maze Methods 0.000 description 4
- 102000008730 Nestin Human genes 0.000 description 4
- 108010088225 Nestin Proteins 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 231100000636 lethal dose Toxicity 0.000 description 4
- 238000007885 magnetic separation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000001178 neural stem cell Anatomy 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 3
- 108010052164 Sodium Channels Proteins 0.000 description 3
- 102000018674 Sodium Channels Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000013016 learning Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 210000005055 nestin Anatomy 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000001360 collision-induced dissociation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 210000001259 mesencephalon Anatomy 0.000 description 2
- DODCBMODXGJOKD-RGMNGODLSA-N methyl (2s)-2-amino-4-methylpentanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC(C)C DODCBMODXGJOKD-RGMNGODLSA-N 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229940084026 sodium valproate Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 230000031836 visual learning Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 241000751613 Echinospartum Species 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001787 epileptiform Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 101150089730 gly-10 gene Proteins 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013580 millipore water Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610645111.7A CN106220713B (zh) | 2016-08-08 | 2016-08-08 | 一种蝎毒耐热合成肽及其用途 |
| PCT/CN2016/112078 WO2018028117A1 (zh) | 2016-08-08 | 2016-12-26 | 一种蝎毒耐热合成肽及其用途 |
| JP2017554073A JP6483858B2 (ja) | 2016-08-08 | 2016-12-26 | サソリ毒耐熱合成ペプチド |
| CA2984569A CA2984569C (en) | 2016-08-08 | 2016-12-26 | A scorpion venom heat-resistant synthetic peptide and applications thereof |
| EP16905684.3A EP3505530B1 (en) | 2016-08-08 | 2016-12-26 | Scorpion venom heat-resistant synthesized peptide and uses thereof |
| ES16905684T ES2945407T3 (es) | 2016-08-08 | 2016-12-26 | Péptido sintético termorresistente del veneno de escorpión y aplicaciones del mismo |
| US15/800,802 US10442837B2 (en) | 2016-08-08 | 2017-11-01 | Scorpion venom heat-resistant synthetic peptide and applications thereof |
| US16/573,495 US10870680B2 (en) | 2016-08-08 | 2019-09-17 | Methods of reducing neuronal injury or toxicity in epilepsy, Alzheimer's disease or Parkinson's disease using a scorpion venom heat-resistant synthetic peptide (SVHRSP) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610645111.7A CN106220713B (zh) | 2016-08-08 | 2016-08-08 | 一种蝎毒耐热合成肽及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106220713A CN106220713A (zh) | 2016-12-14 |
| CN106220713B true CN106220713B (zh) | 2017-09-01 |
Family
ID=57547837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610645111.7A Active CN106220713B (zh) | 2016-08-08 | 2016-08-08 | 一种蝎毒耐热合成肽及其用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10442837B2 (https=) |
| EP (1) | EP3505530B1 (https=) |
| JP (1) | JP6483858B2 (https=) |
| CN (1) | CN106220713B (https=) |
| CA (1) | CA2984569C (https=) |
| ES (1) | ES2945407T3 (https=) |
| WO (1) | WO2018028117A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106220713B (zh) * | 2016-08-08 | 2017-09-01 | 大连医科大学 | 一种蝎毒耐热合成肽及其用途 |
| CN109232718B (zh) * | 2018-11-09 | 2020-04-14 | 泰安市启航生物科技有限公司 | 一种合成肽sp2及其应用 |
| CN111647051B (zh) * | 2019-03-04 | 2022-02-01 | 中国医科大学 | 一种基于钠通道结构的短肽及其应用 |
| CN111896651B (zh) * | 2020-07-30 | 2021-04-23 | 山东大学 | 一种白眉蝮蛇蛇毒类凝血酶特征多肽及其应用 |
| CN114028537B (zh) * | 2021-11-27 | 2024-03-29 | 上海万锦医药科技有限公司 | 一种含有svhrsp蝎毒肽的药物组合物及其制备方法 |
| CN117224655B (zh) * | 2023-09-14 | 2024-05-14 | 大连医科大学 | 蝎毒耐热合成肽(svhrsp)在制备治疗肠道炎症的药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1171595C (zh) * | 2001-02-19 | 2004-10-20 | 大连高新园区全国高技术产业化微生态中试基地 | 获取无毒有效蝎毒的生产工艺及由该工艺制备的治疗癫痫的药物 |
| US20030235902A1 (en) * | 2001-12-13 | 2003-12-25 | Kazuhiko Ishikawa | Heat-resistant thioredoxin and related enzymes |
| CN100465272C (zh) * | 2002-01-18 | 2009-03-04 | 中国科学院上海有机化学研究所 | 重组东亚马氏钳蝎毒rBmKaIT1的基因工程 |
| CN100516217C (zh) * | 2004-09-22 | 2009-07-22 | 山西大学 | 一种人工合成的蝎氯离子通道神经毒素基因-rBmK CTa |
| JP2009509535A (ja) * | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| CN1817902A (zh) * | 2006-03-07 | 2006-08-16 | 山西大学 | 一种重组蝎昆虫毒素及其可溶性表达和纯化方法 |
| CN101450966B (zh) * | 2007-11-29 | 2012-06-27 | 武汉摩尔生物科技有限公司 | 一种抗耐药菌的多肽及用途 |
| CN101284870B (zh) * | 2008-06-03 | 2011-09-14 | 武汉大学 | 一种抗麻疹病毒和人免疫缺陷病毒的多肽及用途 |
| CN103304630B (zh) * | 2012-03-07 | 2014-09-17 | 中国科学院大连化学物理研究所 | 东亚钳蝎蝎毒中的gpcr活性多肽及其提取分离和应用 |
| CN104341495A (zh) | 2013-07-31 | 2015-02-11 | 张万琴 | 一种蝎毒耐热多肽和制备方法及其应用 |
| CN106220713B (zh) * | 2016-08-08 | 2017-09-01 | 大连医科大学 | 一种蝎毒耐热合成肽及其用途 |
-
2016
- 2016-08-08 CN CN201610645111.7A patent/CN106220713B/zh active Active
- 2016-12-26 WO PCT/CN2016/112078 patent/WO2018028117A1/zh not_active Ceased
- 2016-12-26 CA CA2984569A patent/CA2984569C/en active Active
- 2016-12-26 EP EP16905684.3A patent/EP3505530B1/en active Active
- 2016-12-26 ES ES16905684T patent/ES2945407T3/es active Active
- 2016-12-26 JP JP2017554073A patent/JP6483858B2/ja active Active
-
2017
- 2017-11-01 US US15/800,802 patent/US10442837B2/en active Active
-
2019
- 2019-09-17 US US16/573,495 patent/US10870680B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2945407T3 (es) | 2023-07-03 |
| EP3505530B1 (en) | 2023-02-22 |
| EP3505530A4 (en) | 2020-04-29 |
| US10870680B2 (en) | 2020-12-22 |
| EP3505530A1 (en) | 2019-07-03 |
| CA2984569A1 (en) | 2018-02-08 |
| US20180066019A1 (en) | 2018-03-08 |
| US10442837B2 (en) | 2019-10-15 |
| US20200002381A1 (en) | 2020-01-02 |
| WO2018028117A1 (zh) | 2018-02-15 |
| JP6483858B2 (ja) | 2019-03-13 |
| CA2984569C (en) | 2019-10-22 |
| JP2018529626A (ja) | 2018-10-11 |
| CN106220713A (zh) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106220713B (zh) | 一种蝎毒耐热合成肽及其用途 | |
| Nazari et al. | Fingolimod (FTY720) improves hippocampal synaptic plasticity and memory deficit in rats following focal cerebral ischemia | |
| Dong et al. | miR-214-3p promotes the pathogenesis of Parkinson's disease by inhibiting autophagy | |
| CN106632601A (zh) | 一种阻断突触长时程增强（ltp）的短肽及其应用 | |
| US8716216B2 (en) | Human immunosuppressive protein | |
| RU2563348C2 (ru) | ПЕПТИДЫ ИЗ ЯДА СКОРПИОНА Rhopalurus junceus И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ | |
| CN103848914B (zh) | 一种具抗凝活性的菲牛蛭素多肽及其制备方法与用途 | |
| Wang et al. | Ginsenoside Rg1 alleviates chronic stress-induced depression in rats by targeting Cx43-YAP axis | |
| CN106220643A (zh) | 灵芝内酯d及其药物组合物与其在制药和食品中的应用 | |
| CN113651870B (zh) | 一种促进创伤后组织修复与再生的小分子修饰短肽及其应用 | |
| CN110590921A (zh) | 一种人Kv1.3型钾离子通道活性抑制拟肽、其制备方法及应用 | |
| CN102552233A (zh) | 3,4-二羟基苯甲酸甲酯在制备防治神经退行性疾病药物中的应用 | |
| CN104083420A (zh) | 牛膝活性提取物及其制备方法与用途 | |
| CN118027152A (zh) | 一种具有抗炎生物活性的多肽 | |
| CN108715601B (zh) | 一种同时具有抗氧化和抑制Aβ42聚集特性的多肽及其应用与编码该多肽的基因 | |
| CN101757610A (zh) | 蛇毒细胞毒素-ctx1在制备具有镇痛作用药中的应用 | |
| CN106074668B (zh) | 用于神经退行性疾病或神经再生的中药制剂 | |
| CN106399320B (zh) | 一种花狭口蛙的基因及其编码的多肽和该多肽的用途 | |
| CN119979502B (zh) | 一种防治tau疾病的多肽及其应用 | |
| CN119074891A (zh) | 凋亡素组合肽在制备治疗癫痫的药物中的应用 | |
| CN117820428A (zh) | 靶向t-型钙离子通道的蝎毒多肽及其应用 | |
| CN103923176B (zh) | 具有抗乳腺癌活性的寡肽及其应用 | |
| Yu et al. | Bioactive nanovesicles derived from the red alga Pyropia yezoensis for wound healing | |
| CN1191065C (zh) | 川楝素作为引起瘤细胞分化和凋亡的诱导剂的应用 | |
| CN115998769A (zh) | 以Mysm1基因为抑制靶标的物质在提高线粒体活性中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220117 Address after: 201203 China (Shanghai) free trade pilot area, 1 spring 3, 400 Fang Chun road. Patentee after: Shanghai Wanjin Pharmaceutical Technology Co.,Ltd. Address before: 116044, No. 9, west section of Lushun South Road, Lushunkou District, Liaoning, Dalian Patentee before: DALIAN MEDICAL University |
|
| TR01 | Transfer of patent right |